ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 778

Associations Between Autoantibodies and Clinical Manifestations in Systemic Lupus Erythematosus: Data from a Multiethnic Latin American Cohort

Manuel Ugarte-Gil1,2, Daniel Wojdyla3, Ignacio Garcia-Valladares4, Rocio V. Gamboa-Cardenas1, Yelitza Gonzalez-Bello5,6, Guillermo J. Pons-Estel7, Cesar A. Pastor-Asurza1,8, Ignacio Garcia-De La Torre9,10, Graciela S. Alarcon11, Bernado Pons-Estel12 and GLADEL (Grupo Latinoamericano de Estudio de Lupus), 1Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 2Universidad Cientifica del Sur, Lima, Peru, 3Universidad Nacional de Rosario, Argentina, Rosario, Argentina, 4Centro de Estudios de Investigación Básica y Clínica, SC., Guadalajara, Jalisco, Mexico, 5Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Guadalajara, Jalisco, Mexico, 6Immunology and Rheumatlogy, Universidad de Guadalajara, Zapopan, Jalisco, Mexico, 7Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, 8Universidad Nacional Mayor de San Marcos, Lima, Peru, 9Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Zapopan, Jalisco, Mexico, 10Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, 11Medicine, University of Alabama at Birmingham, Birmingham, AL, 12Hospital Provincial de Rosario, Rosario, Argentina

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: outcomes and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Analyses of the association between autoantibodies and SLE clinical
manifestations using cluster analyses assume that centroid and within-cluster
residuals are similar inside the cluster and different between clusters. However,
these antibodies and their combinations within a cluster may have different clinical
impact; moreover, the residuals of two clusters may not be different enough
leading to incorrect conclusions. We have therefore evaluated these associations
individually and in combinations overcoming the problems noted above. 

Methods: Patients with available data for anti-dsDNA, anti-histone, anti-Sm,
anti-RNP, anti-Ro and anti-La from a multinational SLE cohort were included.
Autoantibodies were evaluated individually and in pre-specified combinations (anti-dsDNA
+ anti-histone; anti-Sm + anti-RNP; anti-Ro + anti-La). About 100 clinical
manifestations were systematically recorded using a common protocol. Logistic
regressions were used to examine the association between autoantibodies and clinical
manifestations and components of the last SLICC/ACR Damage Index (SDI) and a
Poisson regression with the last total SDI.  

Results: Three hundred and thirty-eight patients representative of the entire
cohort (n=1480) other than for their ethnic distribution (50.6% vs. 38.1%, Caucasians;
37.9% vs. 45.3%, Mestizo and 11.5%  vs. 16.6%, others p=0.001) were studied.
Of them, 329 (97.3%) fulfilled ≥4ACR criteria. Mean age at diagnosis was 28.5
(SD: 11.5) years, 308 (91.1%) were female; follow-up was 4.6 (1.7) years. Baseline
SLEDAI was 10.5 (7.6) and baseline SDI was 1.0 (1.3). The associations between
clinical manifestations and autoantibodies are depicted in Tables 1 and 2. The
associations between autoantibodies and the last SDI and its components are
depicted in Table 3.



Conclusion: Autoantibodies profiles are associated with different manifestations
and damage among SLE patients. Anti-histone positivity, among anti-dsDNA
positive patients and anti-La positivity were associated with damage accrual,
but anti-Sm positivity among anti-RNP negative patients was negatively
associated with damage accrual. The interaction between autoantibodies should
be evaluated in larger populations in order to evaluate less frequent
manifestations.

 


Disclosure: M. Ugarte-Gil, None; D. Wojdyla, None; I. Garcia-Valladares, None; R. V. Gamboa-Cardenas, None; Y. Gonzalez-Bello, None; G. J. Pons-Estel, None; C. A. Pastor-Asurza, None; I. Garcia-De La Torre, None; G. S. Alarcon, None; B. Pons-Estel, None.

To cite this abstract in AMA style:

Ugarte-Gil M, Wojdyla D, Garcia-Valladares I, Gamboa-Cardenas RV, Gonzalez-Bello Y, Pons-Estel GJ, Pastor-Asurza CA, Garcia-De La Torre I, Alarcon GS, Pons-Estel B. Associations Between Autoantibodies and Clinical Manifestations in Systemic Lupus Erythematosus: Data from a Multiethnic Latin American Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/associations-between-autoantibodies-and-clinical-manifestations-in-systemic-lupus-erythematosus-data-from-a-multiethnic-latin-american-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-autoantibodies-and-clinical-manifestations-in-systemic-lupus-erythematosus-data-from-a-multiethnic-latin-american-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology